首页> 外文OA文献 >THE 5-YEAR FOLLOW-UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA

【2h】

THE 5-YEAR FOLLOW-UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA

机译：C5R方案的5年随访结果与Rituximab和鞘内脂质体糖酸碱淋巴瘤的鞘内脂质半月氨酸氨酸：液化液位的前瞻性第2期

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
H. Ghesquieres; H. Tilly; A. Sonet; J. Dupuis; E. Nicolas-Virelizier; M. Andre; F. Trullemans; J. Eisenmann; R. Delarue; E. Fleck; F. Morschhauser; J. Blay;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). [J] . Ghesquieres H, Ferlay C, Sebban C, Annals of oncology: official journal of the European Society for Medical Oncology . 2010,第4期

机译：对适应年龄的C5R方案进行长期随访，然后对99例新诊断的原发性中枢神经系统淋巴瘤进行放疗：这是对“ Etude des Lymphomes de l'Adulte组”（GELA）的一项前瞻性多中心II期研究。
2. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: an prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [J] . J.-Y. Blay Annals of Oncology . 2010,第4期

机译：对适应年龄的C5R方案进行长期随访，然后在99例新诊断的原发性中枢神经系统淋巴瘤中进行放射治疗：Adulte d'Etude des Lymphomes de l'Adulte（GELA）组的前瞻性多中心II期研究
3. A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401 [J] . Wieduwilt Matthew J., Jonas Brian A., Schiller Gary J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：将Pegymated天酰胺酶，环磷酰胺，rituximab和Dasatinib的II类研究加入到UCSF 8707（Linker 4-药物）方案中，具有脂质体溶血素CNS预防，用于具有新诊断的急性淋巴细胞白血病（ALL）或淋巴细胞淋巴瘤（LBL）：大学加利福尼亚血液学恶性肿瘤联盟研究（UCHMC）1401
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial [O] . E. González-Barca, M. Canales, A. Salar, -1

机译：在一项前瞻性试验中接受一线全身治疗的一部分高风险弥散性大B细胞淋巴瘤高危患者的鞘内脂质体阿糖胞苷预防中枢神经系统
6. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial [O] . Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, 2016

机译：原发性中枢神经系统淋巴瘤患者使用甲氨蝶呤，阿糖胞苷，thiotepa和利妥昔单抗（maTRix方案）进行化学免疫治疗：国际结外淋巴瘤研究组-32（IELsG32）2期试验首次随机化的结果

THE 5-YEAR FOLLOW-UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA

著录项

引文网络

相似文献

相关主题

期刊订阅